Cite
Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients.
MLA
Min Ding, et al. “Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients.” PLoS ONE, vol. 11, no. 12, Jan. 2016, p. e0168798. EBSCOhost, https://doi.org/10.1371/journal.pone.0168798.
APA
Min Ding, Ying Wang, Jiachang Chi, Tao Wang, Xiaoyin Tang, Dan Cui, Qijun Qian, & Bo Zhai. (2016). Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients. PLoS ONE, 11(12), e0168798. https://doi.org/10.1371/journal.pone.0168798
Chicago
Min Ding, Ying Wang, Jiachang Chi, Tao Wang, Xiaoyin Tang, Dan Cui, Qijun Qian, and Bo Zhai. 2016. “Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients.” PLoS ONE 11 (12): e0168798. doi:10.1371/journal.pone.0168798.